Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption
- 1 April 2002
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 55 (4), 210-224
- https://doi.org/10.1002/ddr.10071
Abstract
No abstract availableKeywords
This publication has 75 references indexed in Scilit:
- Zometa® is effective and well tolerated in the prevention of skeletal related events secondary to metastatic breast cancer treated with hormonal therapyEuropean Journal Of Cancer, 2001
- Changes in cross‐sectional geometry of the distal femoral metaphysis associated with inflammatory arthritis are reduced by a bisphosphonate (zoledronate)Journal of Orthopaedic Research, 2000
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Comparative Tolerability of Drug Therapies for Hypercalcaemia of MalignancyDrug Safety, 1999
- Zoledronate Prevents the Development of Absolute Osteopenia Following Ovariectomy in Adult Rhesus MonkeysJournal of Bone and Mineral Research, 1998
- Adverse Effects of BisphosphonatesDrug Safety, 1996
- Metabolism of halogenated bisphosphonates by the cellular slime mould dictyostelium discoideumBiochemical and Biophysical Research Communications, 1992
- Protective Effects of a Prophylactic Treatment with the Bisphosphonate 3-Amino-1 -Hydroxypropane-1,1 -Bisphosphonic Acid on the Development of Tumor Osteopathies in the Rat: Experimental Studies with the Walker Carcinosarcoma 256Oncology, 1988
- The Hypercalcemia of CancerNew England Journal of Medicine, 1984
- Biochemical Evaluation of Patients with Cancer-Associated HypercalcemiaNew England Journal of Medicine, 1980